{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:03:27Z","timestamp":1787025807892,"version":"build-2736575974"},"reference-count":18,"publisher":"Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,22]]},"DOI":"10.31744\/einstein_journal\/2025ao0851","type":"journal-article","created":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T09:44:41Z","timestamp":1745401481000},"source":"Crossref","is-referenced-by-count":3,"title":["Socioeconomic inequities in prostate cancer care: private versus public treatment settings pose a significant impact on overall survival"],"prefix":"10.31744","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-2427-3476","authenticated-orcid":false,"given":"Amanda Caroline de Souza","family":"Costa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4261-4345","authenticated-orcid":false,"given":"Fernando","family":"Korkes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1873-0290","authenticated-orcid":false,"suffix":"Junior","given":"Jose Augusto","family":"Rinck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0731-3734","authenticated-orcid":false,"given":"Frederico Tim\u00f3teo Silva","family":"Cunha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2184-044X","authenticated-orcid":false,"given":"Luciana Holtz de Camargo","family":"Barros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1897-8085","authenticated-orcid":false,"given":"St\u00eanio de C\u00e1ssio","family":"Zequi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1187-1384","authenticated-orcid":false,"given":"Maria Nirvana da Cruz","family":"Formiga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"16942","reference":[{"key":"key20250423134438_B1","author":"Brasil","year":"2023","unstructured":"1. Brasil. Minist\u00e9rio da Sa\u00fade. Instituto Nacional de C\u00e2ncer Jos\u00e9 Alencar Gomes da Silva. Bras\u00edlia (DF): Minist\u00e9rio da Sa\u00fade; 2023."},{"issue":"15","key":"key20250423134438_B2","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","unstructured":"2. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Th\u00e9odore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA; TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502-12.","journal-title":"N Engl J Med"},{"key":"key20250423134438_B3","first-page":"1","article-title":"Radiotheranostics in advanced prostate cancer: current and future directions","volume":"2023","author":"Jia","year":"2023","unstructured":"3. Jia AY, Kiess AP, Li Q, Antonarakis ES. Radiotheranostics in advanced prostate cancer: current and future directions. Prostate Cancer Prostatic Dis. 2023;2023:1-11.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"24","key":"key20250423134438_B4","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1056\/NEJMoa2022485","article-title":"Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer","volume":"383","author":"Hussain","year":"2020","unstructured":"4. Hussain M, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, Chi KN, Sartor O, Agarwal N, Olmos D, Thiery-Vuillemin A, Twardowski P, Roubaud G, \u00d6zg\u00fcroglu M, Kang J, Burgents J, Gresty C, Corcoran C, Adelman CA, de Bono J; PROfound Trial Investigators. Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2020;383(24):2345-57.","journal-title":"N Engl J Med"},{"issue":"10336","key":"key20250423134438_B5","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","article-title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 \u00d7 2 factorial design","volume":"399","author":"Fizazi","year":"2022","unstructured":"5. Fizazi K, Foulon S, Carles J, Roubaud G, McDermott R, Fl\u00e9chon A, Tombal B, Supiot S, Berthold D, Ronchin P, Kacso G, Gravis G, Calabro F, Berdah JF, Hasbini A, Silva M, Thiery-Vuillemin A, Latorzeff I, Mourey L, Laguerre B, Abadie-Lacourtoisie S, Martin E, El Kouri C, Escande A, Rosello A, Magne N, Schlurmann F, Priou F, Chand-Fouche ME, Freixa SV, Jamaluddin M, Rieger I, Bossi A; PEACE-1 investigators. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 \u00d7 2 factorial design. Lancet. 2022;399(10336):1695-107.","journal-title":"Lancet"},{"issue":"12","key":"key20250423134438_B6","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer","volume":"386","author":"Smith","year":"2022","unstructured":"6. Smith MR, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford ED, Kopyltsov E, Park CH, Alekseev B, Montesa-Pino \u00c1, Ye D, Parnis F, Cruz F, Tammela TLJ, Suzuki H, Utriainen T, Fu C, Uemura M, M\u00e9ndez-Vidal MJ, Maughan BL, Joensuu H, Thiele S, Li R, Kuss I, Tombal B; ARASENS Trial Investigators. Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer. N Engl J Med. 2022;386(12):1132-42.","journal-title":"N Engl J Med"},{"issue":"1","key":"key20250423134438_B7","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.eururo.2022.04.002","article-title":"Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021","volume":"82","author":"Gillessen","year":"2022","unstructured":"7. Gillessen S, Armstrong A, Attard G, Beer TM, Beltran H, Bjartell A, et al. Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. Eur Urol. 2022;82(1):115-41.","journal-title":"Eur Urol"},{"issue":"23","key":"key20250423134438_B8","doi-asserted-by":"crossref","first-page":"5556","DOI":"10.1002\/cncr.24607","article-title":"Impact of socioeconomic status on prostate cancer diagnosis, treatment, and prognosis","volume":"115","author":"Rapiti","year":"2009","unstructured":"8 Rapiti E, Fioretta G, Schaffar R, Neyroud-Caspar I, Verkooijen HM, Schmidlin F, et al. Impact of socioeconomic status on prostate cancer diagnosis, treatment, and prognosis. Cancer. 2009;115(23):5556-65.","journal-title":"Cancer"},{"issue":"21","key":"key20250423134438_B9","doi-asserted-by":"crossref","first-page":"3787","DOI":"10.1002\/cncr.34433","article-title":"Racial disparities in Black men with prostate cancer: a literature review","volume":"128","author":"Lillard","year":"2022","unstructured":"9. Lillard JW Jr, Moses KA, Mahal BA, George DJ. Racial disparities in Black men with prostate cancer: a literature review. Cancer. 2022;128(21):3787-95. Review.","journal-title":"Cancer"},{"issue":"3","key":"key20250423134438_B10","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1590\/s1677-5538.ibju.2020.0443","article-title":"Influence of treatment access on survival of metastatic renal cell carcinoma in brazilian cancer center","volume":"47","author":"Leite","year":"2021","unstructured":"10. Leite LM, Bergerot PG, Dettino AL, Rinck Junior JA, Zequi SC, Formiga MN. Influence of treatment access on survival of metastatic renal cell carcinoma in brazilian cancer center. Int Braz J Urol. 2021;47(3):566-73.","journal-title":"Int Braz J Urol"},{"issue":"6","key":"key20250423134438_B11","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.eururo.2009.03.012","article-title":"Pelvic lymph node dissection in prostate cancer","volume":"55","author":"Briganti","year":"2009","unstructured":"11. Briganti A, Blute ML, Eastham JH, Graefen M, Heidenreich A, Karnes JR, et al. Pelvic lymph node dissection in prostate cancer. Eur Urol. 2009;55(6):1251-65.","journal-title":"Eur Urol"},{"issue":"6","key":"key20250423134438_B12","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1111\/j.1464-410X.2007.06771.x","article-title":"Health-insurance status is a determinant of the stage at presentation and of cancer control in European men treated with radical prostatectomy for clinically localized prostate cancer","volume":"99","author":"Gallina","year":"2007","unstructured":"12. Gallina A, Karakiewicz PI, Chun FK, Briganti A, Graefen M, Montorsi F, et al. Health-insurance status is a determinant of the stage at presentation and of cancer control in European men treated with radical prostatectomy for clinically localized prostate cancer. BJU Int. 2007;99(6):1404-8.","journal-title":"BJU Int"},{"issue":"3","key":"key20250423134438_B13","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/cam4.84","article-title":"Cancer survival disparities by health insurance status","volume":"2","author":"Niu","year":"2013","unstructured":"13. Niu X, Roche LM, Pawlish KS, Henry KA. Cancer survival disparities by health insurance status. Cancer Med. 2013;2(3):403-11.","journal-title":"Cancer Med"},{"issue":"7","key":"key20250423134438_B14","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1200\/GO.20.00518","article-title":"Consensus on the Screening, Staging, Treatment, and Surveillance of Localized, Recurrent, and Metastatic Prostate Cancer: The First Global Prostate Cancer Consensus Conference for Developing Countries","volume":"7","author":"Maluf","year":"2021","unstructured":"14. Maluf FC, Gillessen S. Consensus on the Screening, Staging, Treatment, and Surveillance of Localized, Recurrent, and Metastatic Prostate Cancer: The First Global Prostate Cancer Consensus Conference for Developing Countries. JCO Glob Oncol. 2021;7(7):512-5.","journal-title":"JCO Glob Oncol"},{"issue":"4","key":"key20250423134438_B15","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1590\/s1677-5538.ibju.2021.0673","article-title":"Recommendations for prostate cancer diagnosis and treatment during COVID-19 outbreak were not followed in Brazil","volume":"48","author":"Korkes","year":"2022","unstructured":"15. Korkes F, Smaidi K, Timoteo F, Glina S. Recommendations for prostate cancer diagnosis and treatment during COVID-19 outbreak were not followed in Brazil. Int Braz J Urol. 2022;48(4):712-8.","journal-title":"Int Braz J Urol"},{"issue":"2","key":"key20250423134438_B16","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1590\/S1677-55382012000200003","article-title":"Comparison of the epidemiologic features and patterns of initial care for prostate cancer between public and private institutions: a survey by the Brazilian Society of Urology","volume":"38","author":"Nardi","year":"2012","unstructured":"16. Nardi AC, Reis RB, Zequi SC, Nardozza A Jr. Comparison of the epidemiologic features and patterns of initial care for prostate cancer between public and private institutions: a survey by the Brazilian Society of Urology. Int Braz J Urol. 2012;38(2):155-64.","journal-title":"Int Braz J Urol"},{"issue":"8","key":"key20250423134438_B17","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer","volume":"373","author":"Sweeney","year":"2015","unstructured":"17. Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med. 2015;373(8):737-46.","journal-title":"N Engl J Med"},{"issue":"1","key":"key20250423134438_B18","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ccell.2017.06.007","article-title":"Redefining Hormonal Therapy for Advanced Prostate Cancer: results from the LATITUDE and STAMPEDE Studies","volume":"32","author":"Small","year":"2017","unstructured":"18. Small EJ. Redefining Hormonal Therapy for Advanced Prostate Cancer: results from the LATITUDE and STAMPEDE Studies. Cancer Cell. 2017;32(1):6-8.","journal-title":"Cancer Cell"}],"container-title":["einstein (S\u00e3o Paulo)"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T09:44:52Z","timestamp":1745401492000},"score":1,"resource":{"primary":{"URL":"https:\/\/journal.einstein.br\/article\/socioeconomic-inequities-in-prostate-cancer-care-private-versus-public-treatment-settings-pose-a-significant-impact-on-overall-survival\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":18,"alternative-id":["10.31744\/einstein_journal\/2025AO0851"],"URL":"https:\/\/doi.org\/10.31744\/einstein_journal\/2025ao0851","relation":{},"ISSN":["1679-4508","2317-6385"],"issn-type":[{"value":"1679-4508","type":"print"},{"value":"2317-6385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"article-number":"eAO0851"}}